ISTx registers Phase 3 trial of ceftobiprole in pediatric Staphylococcus aureus bacteremia
The study, led by ISTx, LLC, plans to enroll 60 participants and begin on October 30, 2026, to compare ceftobiprole with standard-of-care antibiotics in children under 18 with Staphylococcus aureus bacteremia, including right-sided infective endocarditis. The trial will also evaluate safety, tolerability, efficacy, and pharmacokinetics of ceftobiprole.
Primary source
ClinicalTrials.gov registry record, November 10, 2026
A Study of Ceftobiprole Compared With Standard Antibiotic Treatment in Children With Staphylococcus Aureus Bacteremia (SAB) Infection, Including Right-sided Heart Infection
Machine-summarized from the source above; not independently reported. How we use automation